🔎 Trials Near Me

Home › Non-Small Cell Lung Cancer › Texas › Fort Worth

Non-Small Cell Lung Cancer clinical trials in Fort Worth, TX

18 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Fort Worth (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

RecruitingPhase 1
  • START Center for Clinical Research, Fort Worth
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

RecruitingPhase 3
  • The Center For Cancer And Blood Disorders, Fort Worth
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361497

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

RecruitingPhase 2
  • START Fort Worth, Fort Worth
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07659782

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

RecruitingPhase 3
  • Texas Oncology - DFW, Fort Worth
  • The Center for Cancer and Blood Disorders, Fort Worth
  • The Center for Cancer and Blood Disorders, Burleson · 13 mi away
  • and 1 more
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

RecruitingPhase 3
  • The Center for Cancer and Blood Disorders, Fort Worth
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

RecruitingPhase 3
  • Clinical Study Site, Fort Worth
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06767514

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

RecruitingPhase 1/2
  • Start Dfw, Fort Worth
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06303505

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

RecruitingPhase 1
  • Texas Oncology - DFW, Fort Worth
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT05245500

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

RecruitingPhase 1/2
  • USOR Texas Oncology, Fort Worth
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

RecruitingPhase 1
  • UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05208762

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

RecruitingPhase 2
  • Start Ccbd, Llc, Fort Worth
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT07452224

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

RecruitingPhase 1
  • START Dallas Fort Worth, LLC, Fort Worth
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07503808

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

RecruitingPhase 1
  • START Dallas Fort Worth, LLC, Fort Worth
Ages 18 to 99 · All sexes · Updated Jun 16, 2026 · NCT07540572

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

RecruitingPhase 1
  • START Dallas, Fort Worth
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT07517198

Non-Small Cell Lung Cancer trials in other cities

Other studies in Fort Worth

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.